Cyclerion merger faces probe over 1.5% shareholder stake

Halper Sadeh LLC is investigating Cyclerion Therapeutics Inc.’s (NASDAQ: CYCN) planned merger with Korsana Biosciences, a deal that would leave Cyclerion shareholders with only 1.5% of the combined company.

The investor rights law firm said it is investigating the fairness of the transaction for Cyclerion shareholders and encourages those with concerns to contact them.

The investigation focuses on the all-stock transaction that will see the neuro-focused Cyclerion absorbed by the privately-held Korsana. Upon closing, current Cyclerion shareholders’ ownership will be diluted to approximately 1.5%, with Korsana's backers and investors in a concurrent private placement holding the vast majority of the new entity.

This probe introduces significant uncertainty for the reverse merger, which the companies expect to complete in the third quarter. The investigation could lead to shareholder lawsuits seeking to halt the deal or renegotiate its terms, creating potential headwinds for Cyclerion’s stock.

The proposed merger would have the combined company operate under the Korsana brand and trade on Nasdaq under the ticker “KRSA.” In support of the deal, Korsana secured a $380 million private investment from a syndicate led by Fairmount and Venrock Healthcare Capital Partners.

For Cyclerion, the merger follows a strategic review after a series of pivots. The company shifted from mitochondria-related diseases in 2022 to neuropsychiatry in 2023 before pursuing the current transaction. Cyclerion CEO Regina Graul said in a prior statement that the deal with Korsana represents the best path forward for shareholders.

The investigation highlights concerns that the deal may undervalue Cyclerion's assets or unfairly benefit Korsana's private investors. Shareholders will be watching for any formal legal challenges or revised merger proposals ahead of the expected third-quarter close.

This article is for informational purposes only and does not constitute investment advice.